Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis B
Lung-Yi Mak, Danny Wong, Alison Kuchta, Martina Hilfiker, Aaron Hamilton, Ning Chow, XianHua Mao, Wai Kay Seto, Man-Fung Yuen
Clin Mol Hepatol. 2023;29(1):146-162.   Published online 2022 Aug 19     DOI: https://doi.org/10.3350/cmh.2022.0172
Citations to this article as recorded by Crossref logo
Biogenesis of serum HBV RNA and clinical phenomena of serum HBV RNA in chronic hepatitis B patients before and after receiving nucleos(t)ide analogues therapy
Liandong Wu, Zhenggang Yang, Min Zheng
Journal of Viral Hepatitis.2024; 31(5): 255.     CrossRef
Letter regarding “Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation”
Yun-Fan Liaw
Clinical and Molecular Hepatology.2024; 30(2): 269.     CrossRef
Circulating HBV RNA and Hepatitis B Core–Related Antigen Trajectories in Persons With HIV/HBV Coinfection and Hepatitis B Surface Antigen Loss During Tenofovir Therapy
Lorin Begré, Anders Boyd, Marie-Laure Plissonnier, Barbara Testoni, Luisa Salazar-Vizcaya, Franziska Suter-Riniker, Caroline Scholtès, Charles Béguelin, Jürgen K Rockstroh, Huldrych F Günthard, Alexandra Calmy, Matthias Cavassini, Hans H Hirsch, Patrick S
The Journal of Infectious Diseases.2024;[Epub]     CrossRef
Correspondence on Editorial regarding “HBV pgRNA and HBcrAg reductions at week 4 predict favourable HBsAg response upon long-term nucleos(t)ide analogue in CHB”
Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen
Clinical and Molecular Hepatology.2023; 29(1): 191.     CrossRef
New biomarkers of hepatitis B virus (HBV) infection: HBV RNA and HBV core-related antigen, new kids on the block?
Young-Suk Lim
Clinical and Molecular Hepatology.2023; 29(1): 118.     CrossRef
Moving toward hepatitis B virus functional cure - the impact of on-treatment kinetics of serum viral markers
Lilian Yan Liang, Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Terry Cheuk-Fung Yip
Clinical and Molecular Hepatology.2023; 29(1): 113.     CrossRef
Advances in determining new treatments for hepatitis B infection by utilizing existing and novel biomarkers
Lung-Yi Mak, Rex Wan-Hin Hui, Ka-Shing Cheung, James Fung, Wai-Kay Seto, Man-Fung Yuen
Expert Opinion on Drug Discovery.2023; 18(4): 401.     CrossRef
Utility of novel viral and immune markers in predicting HBV treatment endpoints: A systematic review of treatment discontinuation studies
Georgia Zeng, Apostolos Koffas, Lung-Yi Mak, Upkar S. Gill, Patrick T.F. Kennedy
JHEP Reports.2023; 5(6): 100720.     CrossRef
The role of different viral biomarkers on the management of chronic hepatitis B
Lung-Yi Mak, Rex Wan-Hin Hui, James Fung, Wai Kay Seto, Man-Fung Yuen
Clinical and Molecular Hepatology.2023; 29(2): 263.     CrossRef
Past, present, and future of long-term treatment for hepatitis B virus
Teresa Broquetas, José A Carrión
World Journal of Gastroenterology.2023; 29(25): 3964.     CrossRef